Germ-cell tumors in childhood and adolescence

Citation
U. Gobel et al., Germ-cell tumors in childhood and adolescence, ANN ONCOL, 11(3), 2000, pp. 263-271
Citations number
43
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
ANNALS OF ONCOLOGY
ISSN journal
09237534 → ACNP
Volume
11
Issue
3
Year of publication
2000
Pages
263 - 271
Database
ISI
SICI code
0923-7534(200003)11:3<263:GTICAA>2.0.ZU;2-9
Abstract
In mature and immature teratoma the treatment is surgical. The risk of recu rrence can be estimated from the parameters primary site (with the coccygea l tumors being most at risk), histological grade of immaturity and complete ness of the primary resection including the adjacent organ of origin (coccy x, ovary, testis etc.). In case of a microscopically complete tumor resecti on there is no role for adjuvant chemo- or radiotherapy irrespective of the histological grade of immaturity. Malignant germ-cell tumors (GCT) account for 2.9% of all malignant tumors o f children younger than 15 years of age. More than half of the tumors occur at extragonadal sites such as the ovaries (26%), the coccygeal region (24% ), the testes (18%) and the brain (18%) represent then primary sites. In patients with extensive tumor growth, metastatic disease or secreting in tracranial tumors a delayed tumor resection after preoperative chemotherapy is preferable. In these patients malignant non-seminomatous GCT may be dia gnosed clinically due to the increased serum or cerebrospinal fluid levels of the tumor markers AFP and/or beta-HCG. Current risk adapted treatment pr otocols containing cisplatinum allow long-term remissions in about 80% incl uding patients with bulky or metastatic tumors. In the cisplatinum era the prognostic factors like histology, primary site of the tumor and initial tu mor stage have partly lost their former impressive significance in infants and children. On the other hand the completeness of the primary tumor resec tion according to oncological standards has been established as the most po werful prognostic parameter superior to tumor marker levels or primary site of the tumor.